BCL2 and diffuse large B-cell lymphoma: Altogether, our work supports a wider therapeutic concept, in which the status of MYC and BCL2‐family members in individual patients may guide the decision to combine OxPhos inhibitors and select BH3‐mimetics against high‐grade DLBCL, and possibly other refractory malignancies.